Wedbush Lowers Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $36.00

Dianthus Therapeutics (NASDAQ:DNTH) had its price target reduced by investment analysts at Wedbush from $38.00 to $36.00 in a report released on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s target price points to a potential upside of 30.91% from the company’s previous close.

A number of other research analysts have also recently issued reports on the stock. Raymond James lifted their target price on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a research note on Thursday, April 18th. Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 target price for the company. Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Cantor Fitzgerald assumed coverage on shares of Dianthus Therapeutics in a research note on Thursday, June 27th. They issued an “overweight” rating for the company. Finally, Lifesci Capital upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Buy” and an average price target of $44.71.

Dianthus Therapeutics Stock Up 2.8 %

DNTH traded up $0.76 during midday trading on Friday, reaching $27.50. 145,393 shares of the company’s stock were exchanged, compared to its average volume of 194,359. The firm has a market capitalization of $807.10 million, a price-to-earnings ratio of -4.72 and a beta of 1.89. Dianthus Therapeutics has a one year low of $6.58 and a one year high of $33.77. The business has a 50-day simple moving average of $26.34 and a two-hundred day simple moving average of $25.05.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The business had revenue of $0.87 million for the quarter, compared to analysts’ expectations of $0.48 million. As a group, research analysts anticipate that Dianthus Therapeutics will post -2.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC bought a new position in Dianthus Therapeutics in the 4th quarter worth approximately $25,000. SG Americas Securities LLC acquired a new stake in Dianthus Therapeutics during the 2nd quarter worth $112,000. WINTON GROUP Ltd acquired a new stake in Dianthus Therapeutics during the 2nd quarter worth $265,000. Virtu Financial LLC acquired a new stake in Dianthus Therapeutics during the 1st quarter worth $390,000. Finally, Hussman Strategic Advisors Inc. acquired a new stake in Dianthus Therapeutics during the 1st quarter worth $630,000. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.